MX2010009518A - Quinolinas como inhibidoras de farnesil-pirofosfato-sintasa. - Google Patents

Quinolinas como inhibidoras de farnesil-pirofosfato-sintasa.

Info

Publication number
MX2010009518A
MX2010009518A MX2010009518A MX2010009518A MX2010009518A MX 2010009518 A MX2010009518 A MX 2010009518A MX 2010009518 A MX2010009518 A MX 2010009518A MX 2010009518 A MX2010009518 A MX 2010009518A MX 2010009518 A MX2010009518 A MX 2010009518A
Authority
MX
Mexico
Prior art keywords
quinolines
inhibitors
farnesyl pyrophosphate
pyrophosphate synthase
farnesyl
Prior art date
Application number
MX2010009518A
Other languages
English (en)
Inventor
Guido Bold
Johann Zimmermann
Silvio Ofner
Frederic Stauffer
Wolfgang Jahnke
Andreas Marzinzik
Simona Cotesta
Rene Amstutz
Constanze Mueller-Hartwieg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010009518A publication Critical patent/MX2010009518A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula (I): en donde los sustituyentes son como se describen en la memoria descriptiva, los cuales son útiles como moduladores de la farnesilpirofosfato-sintasa, por ejemplo, en el tratamiento de enfermedades proliferativas, a los métodos para la elaboración de estos compuestos, y a los intermediarios de los mismos.
MX2010009518A 2008-02-28 2009-02-26 Quinolinas como inhibidoras de farnesil-pirofosfato-sintasa. MX2010009518A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152046 2008-02-28
PCT/EP2009/052314 WO2009106586A1 (en) 2008-02-28 2009-02-26 Quinolines as inhibitors of farnesyl pyrophosphate synthase

Publications (1)

Publication Number Publication Date
MX2010009518A true MX2010009518A (es) 2010-09-14

Family

ID=39636965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009518A MX2010009518A (es) 2008-02-28 2009-02-26 Quinolinas como inhibidoras de farnesil-pirofosfato-sintasa.

Country Status (11)

Country Link
US (1) US20120094958A1 (es)
EP (1) EP2250152A1 (es)
JP (1) JP2011514893A (es)
KR (1) KR20100124732A (es)
CN (1) CN101959865A (es)
AU (1) AU2009218468A1 (es)
BR (1) BRPI0908396A2 (es)
CA (1) CA2717011A1 (es)
EA (1) EA201001362A1 (es)
MX (1) MX2010009518A (es)
WO (1) WO2009106586A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102414180A (zh) * 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
CN104142378B (zh) * 2014-07-29 2015-12-30 华南理工大学 薄层色谱法半定量测定氨基甲酸乙酯的方法
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof
CN111440161B (zh) * 2020-05-15 2023-04-14 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
CN112980809B (zh) * 2021-03-17 2023-04-11 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254544A (en) * 1992-09-25 1993-10-19 E. R. Squibb & Sons, Inc. Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method
US20020151459A1 (en) * 2000-02-25 2002-10-17 Merck & Co., Inc. Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase

Also Published As

Publication number Publication date
KR20100124732A (ko) 2010-11-29
WO2009106586A1 (en) 2009-09-03
BRPI0908396A2 (pt) 2019-03-06
EP2250152A1 (en) 2010-11-17
CN101959865A (zh) 2011-01-26
AU2009218468A1 (en) 2009-09-03
CA2717011A1 (en) 2009-09-03
US20120094958A1 (en) 2012-04-19
JP2011514893A (ja) 2011-05-12
EA201001362A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MY148253A (en) Azaadamantane derivatives and methods of use
EP3483143A8 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
SG10201407927UA (en) Imidazopyridine derivatives as jak inhibitors
SG171593A1 (en) Inhibitors of c-fms kinase
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX2013015147A (es) Procesos y compuestos intermediarios para producir azaindoles.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MY156954A (en) PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSES
MX2012004780A (es) Inhibidores de akt.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MY160392A (en) Triptolide prodrugs
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2010009518A (es) Quinolinas como inhibidoras de farnesil-pirofosfato-sintasa.
TN2014000410A1 (en) Pyrazole compounds as sglt1 inhibitors
IN2013DE02503A (es)
EA201100615A1 (ru) Производные салициловой кислоты в качестве ингибиторов активности фарнезилпирофосфатсинтазы

Legal Events

Date Code Title Description
FA Abandonment or withdrawal